

## Surveillance report

Surveillance generated by nf-ncov-voc for Mu variant

### Date

This report is generated on 2023-03-04 using 459574 number of genomes collected between 2020-02-25 and 2023-02-16

## Pango Lineages

Pango Lineages in this report ['B.1.621', 'B.1.621.1', 'B.1.621.2', 'BB.2']

## Indicator

This table contains key indicators identified

Indicator	Sub-categories from POKAY	Mutations
Transmissibility between humans	transmissibility	D614G, E484K, K417N, L452R, N501Y
Infection Severity	ACE2 receptor binding affinity, viral load, outcome hazard ratio	D614G, E484K, K417N, L452R, N501Y, P681H, Q677H, S494P, T1027I, T95I
Immunity after natural infection	convalescent plasma escape, reinfection, humoral response durability	D614G, E484K, K417N, L452R, N501Y, Q677H, S494P
Vaccines	vaccine neutralization efficacy	D614G, E484K, K417N, L452R, N501Y, P681H
Monoclonal antibodies	monoclonal antibody serial passage escape, pharmaceutical effectiveness	E484K, K417N, L452R, N501Y, R346K, S494P
Diagnostics	clinical indicators, antigenic test failure, symptom prevalence	

## Mutation Significance

This table contains key functional impacts of mutations identified

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
N501Y	ACE2 receptor binding affinity	The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity extasciitilde10 fold to KD extasciitilde7 nM, by increasing the k(on) extasciitilde1.8 fold and decreasing the k(off) by extasciitilde 7 fold as measured by surface plasmon resonance.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Barton et al. (2021)	143	A	T	0.99
N501Y	ACE2 receptor binding affinity	In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to extasciitilde15 fold higher than WT RBD (KD extasciitilde5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Barton et al. (2021)	143	A	T	0.99
N501Y	ACE2 receptor binding affinity	The affinity of the B.1.351 RBD variants for ACE2 increased by 3.7 fold as measured by surface plasmon resonance relative to wild type RBD by increasing the k(on) and decreasing the k(off) rate constants.	B.1.621	Barton et al. (2021)	122	A	T	0.99

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
N501Y	ACE2 receptor binding affinity	This combination showed extasciitilde3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	B.1.621, BB.2, B.1.621.2, B.1.621.1	Collier et al. (2021)	143	A	T	0.99
N501Y	ACE2 receptor binding affinity	The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Gamez et al. (2021)	143	A	T	0.99
N501Y	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in "off-rate" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).	B.1.621, BB.2, B.1.621.2, B.1.621.1	Gong et al. (2021)	143	A	T	0.99
N501Y	ACE2 receptor binding affinity	RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor, while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds 3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Laffeber et al. (2021)	143	A	T	0.99
N501Y	ACE2 receptor binding affinity	Reported 10-fold increase in ACE2 binding vs wild-type (Kd	B.1.621, BB.2, B.1.621.2, B.1.621.1	Liu et al. (2021)	143	A	T	0.99
N501Y	ACE2 receptor binding affinity	Studying the key covariants in lineage of concern 501Y.V2, observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Liu et al. (2021)	143	A	T	0.99
N501Y	ACE2 receptor binding affinity	extasciitilde4-fold increase in binding affinity vs wild type.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Motozono et al. (2021)	143	A	T	0.99
N501Y	ACE2 receptor binding affinity	Using Microscale Thermophoresis, this variant binds ACE2 at nearly two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).	B.1.621, BB.2, B.1.621.2, B.1.621.1	Ramanathan et al. (2021)	143	A	T	0.99
N501Y	ACE2 receptor binding affinity	Using Mircoscale Thermophoresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	B.1.621, BB.2, B.1.621.2, B.1.621.1	Ramanathan et al. (2021)	143	A	T	0.99

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
N501Y	ACE2 receptor binding affinity	In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501 mutant residue with the ACE2 receptor, which in this strain is increased.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Santos and Passos (2021)	143	A	T	0.99
N501Y	ACE2 receptor binding affinity	Experimentally, ACE2 binding affinity increased 0.24 fold	B.1.621, BB.2, B.1.621.2, B.1.621.1	Starr et al. (2020)	143	A	T	0.99
N501Y	ACE2 receptor binding affinity	This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus, but combined with the complete set of B.1.1.7 lineage variants no major change vs wild type affinity is observed.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Tada et al. (2021)	143	A	T	0.99
N501Y	ACE2 receptor binding affinity	Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells for ACE2 affinity changes vs D614G alone, showing a 70% drop in IC50 (i.e. increased affinity).	B.1.621	Tada et al. (2021)	122	A	T	0.99
N501Y	ACE2 receptor binding affinity	Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd	B.1.621, BB.2, B.1.621.2, B.1.621.1	Tian et al. (2021)	143	A	T	0.99
N501Y	ACE2 receptor binding affinity	Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd	B.1.621, BB.2, B.1.621.2, B.1.621.1	Tian et al. (2021)	143	A	T	0.99
N501Y	ACE2 receptor binding affinity	The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Vogel et al. (2021)	143	A	T	0.99
N501Y	ACE2 receptor binding affinity	Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd	B.1.621, BB.2, B.1.621.2, B.1.621.1	Zahradnik et al. (2021)	143	A	T	0.99
N501Y	ACE2 receptor binding affinity	N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2. The additional interactions result in increased affinity of ACE2 for the N501Y mutant, accounting for its increased infectivity.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Zhu et al. (2021)	143	A	T	0.99

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
N501Y	T cell evasion	Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool, T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p	B.1.621, BB.2, B.1.621.2, B.1.621.1	Reynolds et al. (2021)	143	A	T	0.99
N501Y	antibody epitope effects	Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Chen et al. (2021)	143	A	T	0.99
N501Y	antibody epitope effects	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Chen et al. (2021)	143	A	T	0.99
N501Y	antibody epitope effects	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58.	B.1.621	Chen et al. (2021)	122	A	T	0.99
N501Y	antibody epitope effects	Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Collier et al. (2021)	143	A	T	0.99
N501Y	antibody epitope effects	Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B.1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Haynes et al. (2021)	143	A	T	0.99
N501Y	antibody epitope effects	Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.	B.1.621	Hu et al. (2021)	122	A	T	0.99
N501Y	antibody epitope effects	Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Klegerman et al. (2021)	143	A	T	0.99
N501Y	antibody epitope effects	Lowered the neutralization potency of mAb COVA1-12 to the limit of the assay. Decrease in potency was observed against the N501Y pseudotype for the cluster IX mAb COVA2-17.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Rees-Spear et al. (2021)	143	A	T	0.99
N501Y	antibody epitope effects	Reduction in neutralization by mAbs COVA1-18 ( extasciitilde4x), COVA2-15 ( extasciitilde9x), S309 ( extasciitilde3x)	B.1.621, BB.2, B.1.621.2, B.1.621.1	Shen et al. (2021)	143	A	T	0.99

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
N501Y	antibody epitope effects	Complete loss of binding in ELISA by the variant against monoclonal antibodies ab8 and IgG1 ab1. Complete loss for the same antibodies was also observed against S1 pseudotyped and full Spike protein trimers with both B.1.351 and P.1 lineage variants, with slight binding signal for P.1 against IgG1 at the highest concentration tested (1uM). Complete loss of neutralization by these two antibodies was also observed.	B.1.621	Sun et al. (2021)	122	A	T	0.99
N501Y	antibody epitope effects	4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3	B.1.621, BB.2, B.1.621.2, B.1.621.1	Wang et al. (2021)	143	A	T	0.99
N501Y	antibody epitope effects	Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 ("South African") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 ("South African") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 ("South African") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 ("South African") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 ("South African") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 ("South African") lineage background	B.1.621	Wibmer et al. (2021)	122	A	T	0.99
N501Y	convalescent plasma binding	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Gong et al. (2021)	143	A	T	0.99
N501Y	convalescent plasma escape	Average extasciitilde10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	B.1.621	Alenquer et al. (2021)	122	A	T	0.99
N501Y	convalescent plasma escape	The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	B.1.621, BB.2, B.1.621.2, B.1.621.1	Cele et al. (2021)	143	A	T	0.99

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
N501Y	convalescent plasma escape	In 19 convalescent human sera extasciitilde1mo post infection had mild to moderate resistance against all samples.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Chen et al. (2021)	143	A	T	0.99
N501Y	convalescent plasma escape	In 19 convalescent human sera extasciitilde1mo post infection had mild to moderate resistance against most samples	B.1.621	Chen et al. (2021)	122	A	T	0.99
N501Y	convalescent plasma escape	Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera collected extasciitilde8mo post Jan 2020 first wave in China).	B.1.621	Hu et al. (2021)	122	A	T	0.99
N501Y	convalescent plasma escape	0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe disease 21 to 63 days post-onset.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kuzmina et al. (2021)	143	A	T	0.99
N501Y	convalescent plasma escape	extasciitilde7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant.	B.1.621	Kuzmina et al. (2021)	122	A	T	0.99
N501Y	convalescent plasma escape	In 30 samples collected 111 to 260 days post onset of symptoms, the convalescent plasma can neutralize both the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Rathnasinghe et al. (2021)	143	A	T	0.99
N501Y	convalescent plasma escape	Neutralization activity of convalescent sera tested decreased extasciitilde2x with this B.1.1.7 pseudotyped virus.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Shen et al. (2021)	143	A	T	0.99
N501Y	convalescent plasma escape	Viruses containing the point mutations of B.1.1.7 showed that the single point mutations ( $\Delta$ 69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Tada et al. (2021)	143	A	T	0.99
N501Y	convalescent plasma escape	Lentiviral pseudotyped with the key mutations from COH.20G/677H ("Ohio") lineage was neutralized similarly to D614G in 10 convalescent sera from April 2020 infectees.	B.1.621	Tada et al. (2021)	122	A	T	0.99
N501Y	convalescent plasma escape	As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Tang et al. (2021)	143	A	T	0.99

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
N501Y	convalescent plasma escape	Demonstrate (via competitive assays in human and mouse) immune escape from polyclonal antibodies induced by vaccination or infection, comparable to what was previously shown with monoclonal antibodies for N501Y and more importantly for E484K. Even though viral mutations may more strongly affect monoclonal antibodies than sera activity, the latter may also be reduced as confirmed here.	B.1.621	Vogel et al. (2021)	122	A	T	0.99
N501Y	convalescent plasma escape	27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutants of the 501Y.V2 "South African" lineage), while only 23% retained high titres	B.1.621, BB.2, B.1.621.2, B.1.621.1	Wibmer et al. (2021)	143	A	T	0.99
N501Y	convalescent plasma escape	Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 ("South African") lineage pseudovirus construct. Only 3 of 44 convalescent sera (those with the highest titer, which correlated directly with initial infection severity) had high neutralization against this 501Y.V2 PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Wibmer et al. (2021)	143	A	T	0.99
N501Y	environmental condition stability	Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour	B.1.621, BB.2, B.1.621.2, B.1.621.1	Tada et al. (2021)	143	A	T	0.99
N501Y	homoplasmy	Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia (same origin as UK), and South Africa (independent origin).	B.1.621, BB.2, B.1.621.2, B.1.621.1	Flores-Alanis et al. (2021)	143	A	T	0.99
N501Y	immunosuppression variant emergence	Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome	B.1.621, BB.2, B.1.621.2, B.1.621.1	Choi et al. (2020)	143	A	T	0.99
N501Y	monoclonal antibody serial passage escape	In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Wang et al. (2021)	143	A	T	0.99
N501Y	pharmaceutical effectiveness	COR-101 lost extascitilde8x binding against this isolated mutation. Regdanvimab lost extascitilde8x binding against this isolated mutation.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Engelhart et al. (2021)	143	A	T	0.99
N501Y	pharmaceutical effectiveness	Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Engelhart et al. (2021)	143	A	T	0.99

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
N501Y	pharmaceutical effectiveness	Bamlanivimab (LY-CoV555) lost extasciitilde64x binding against this double mutation. COR-101 lost extasciitilde50x binding against this double mutation. Casirivimab lost extasciitilde250x binding against this double mutation. Estesevimab lost extasciitilde16x binding against this double mutation. Regdanvimab lost extasciitilde32x binding against this double mutation. Tixagevimab lost extasciitilde10x binding against this double mutation.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Engelhart et al. (2021)	143	A	T	0.99
N501Y	pharmaceutical effectiveness	COR-101 lost extasciitilde20x binding against this double mutation. Estesevimab lost extasciitilde16x binding against this double mutation. Regdanvimab lost extasciitilde6x binding against this double mutation. M396 lost extasciitilde10x binding against this double mutation.	B.1.621	Engelhart et al. (2021)	122	A	T	0.99
N501Y	pharmaceutical effectiveness	This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Liu et al. (2021)	143	A	T	0.99
N501Y	syncytium formation	Slight increase in Vero cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kim et al. (2021)	143	A	T	0.99
N501Y	syncytium formation	extasciitilde50% Vero cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, significantly higher than D614G.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kim et al. (2021)	143	A	T	0.99
N501Y	trafficking	The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.	B.1.621	Hu et al. (2021)	122	A	T	0.99
N501Y	trafficking	More efficient infectivity (24h) compared to wild type, in Caco-2 cells extasciitilde9x, Vero extasciitilde8x, and Calu-3 extasciitilde8x. Compare to wild type at extasciitilde5x across cell types.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kim et al. (2021)	143	A	T	0.99
N501Y	trafficking	extasciitilde4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kim et al. (2021)	143	A	T	0.99
N501Y	trafficking	More efficient infectivity (24h) compared to wild type, in Caco-2 cells extasciitilde11x, Vero extasciitilde10x, and Calu-3 extasciitilde11x. Compare to wild type at extasciitilde5x across cell types.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kim et al. (2021)	143	A	T	0.99



Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
N501Y	trafficking	extasciitilde6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kim et al. (2021)	143	A	T	0.99
N501Y	trafficking	9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kuzmina et al. (2021)	147	A	T	0.99
N501Y	trafficking	extasciitilde12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction ( extasciitildeadditive effects of 501 and 484).	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kuzmina et al. (2021)	143	A	T	0.99
N501Y	trafficking	extasciitilde13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.	B.1.621	Kuzmina et al. (2021)	122	A	T	0.99
N501Y	trafficking	extasciitilde9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).	B.1.621	Kuzmina et al. (2021)	122	A	T	0.99
N501Y	trafficking	Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Motozono et al. (2021)	143	A	T	0.99
N501Y	trafficking	Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection, showing slightly increased infection rate amongst the cells. [in what is essentially a replicate experiment in the same paper, because each B.1.351 lineage variant was independently evaluated and N501 is in both lineages, a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully]	B.1.621, BB.2, B.1.621.2, B.1.621.1	Tada et al. (2021)	143	A	T	0.99
N501Y	trafficking	Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection, showing no significant change in infection rate amongst the cells, suggesting that this mutation does not contributing to cell entry fitness.	B.1.621	Tada et al. (2021)	122	A	T	0.99
N501Y	transmissibility	Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure.	B.1.621	Pearson et al. (2021)	122	A	T	0.99

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
N501Y	transmissibility	36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021 in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.	B.1.621	Roquebert et al. (2021)	122	A	T	0.99
N501Y	vaccine neutralization efficacy	Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Bates et al. (2021)	143	A	T	0.99
N501Y	vaccine neutralization efficacy	Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus.	B.1.621	Bates et al. (2021)	122	A	T	0.99
N501Y	vaccine neutralization efficacy	The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P	B.1.621, BB.2, B.1.621.2, B.1.621.1	Chen et al. (2021)	143	A	T	0.99
N501Y	vaccine neutralization efficacy	1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine at a dose of 100 µg (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone) relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Edara et al. (2021)	143	A	T	0.99
N501Y	vaccine neutralization efficacy	The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northern California during the study period, suggesting no effect of these variants on immune escape.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Jacobson et al. (2021)	143	A	T	0.99

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
N501Y	vaccine neutralization efficacy	The presence of these B.1.417/B.1.429 defining variants in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northern California during the study period, suggesting no effect of these variants on immune escape.	B.1.621	Jacobson et al. (2021)	122	A	T	0.99
N501Y	vaccine neutralization efficacy	This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kuzmina et al. (2021)	143	A	T	0.99
N501Y	vaccine neutralization efficacy	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kuzmina et al. (2021)	143	A	T	0.99
N501Y	vaccine neutralization efficacy	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n	B.1.621	Kuzmina et al. (2021)	122	A	T	0.99
N501Y	vaccine neutralization efficacy	In post-vaccination sera from individuals who received one (3 weeks post-first dose: n	B.1.621	Kuzmina et al. (2021)	122	A	T	0.99
N501Y	vaccine neutralization efficacy	This variant of key B.1.351 lineage mutations showed extasciitilde10x decrease in Pfizer sera (3 weeks post-first dose: n	B.1.621	Kuzmina et al. (2021)	122	A	T	0.99
N501Y	vaccine neutralization efficacy	In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from extasciitilde2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This RBD variant combination's neutralization by a placebo control group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	B.1.621	Madhi et al. (2021)	122	A	T	0.99
N501Y	vaccine neutralization efficacy	Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Rathnasinghe et al. (2021)	143	A	T	0.99

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
N501Y	vaccine neutralization efficacy	In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines, a modest decrease in neutralization by vaccine plasma was observed.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Wang et al. (2021)	143	A	T	0.99
N501Y	vaccine neutralization efficacy	In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines, a significant (0.5 to 20-fold, but average extasciitilde2x) decrease in neutralization by vaccine plasma was observed.	B.1.621	Wang et al. (2021)	122	A	T	0.99
N501Y	vaccine neutralization efficacy	In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases, titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of extasciitilde1/300.	B.1.621	Wu et al. (2021)	122	A	T	0.99
N501Y	vaccine neutralization efficacy	In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Xie et al. (2021)	143	A	T	0.99
N501Y	vaccinee plasma binding	1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Gong et al. (2021)	143	A	T	0.99
N501Y	viral load	B.1.351 and P.1 samples showed average Ct cycle threshold of 22.2 vs 23 for wildtype (i.e. extasciitilde60% higher viral load) comparing 3360 and 22535 samples respectively.	B.1.621	Roquebert et al. (2021)	122	A	T	0.99
N501Y	viral load	The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a extasciitilde2-fold viral load increase ( extasciitilde1 Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26).	B.1.621	Teyssou et al. (2021)	122	A	T	0.99
N501Y	virion structure	Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type)	B.1.621, BB.2, B.1.621.2, B.1.621.1	Spratt et al. (2021)	143	A	T	0.99

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
D614G	ACE2 receptor binding affinity	This variant appears twice in the experiments, with slightly different affinities (both extasciitilde1.2x decrease in binding relative to D614G) using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Gong et al. (2021)	147	A	G	1.0
D614G	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.	B.1.621	Gong et al. (2021)	126	A	G	1.0
D614G	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.	B.1.621	Gong et al. (2021)	126	A	G	1.0
D614G	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in "off-rate" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).	B.1.621, BB.2, B.1.621.2, B.1.621.1	Gong et al. (2021)	147	A	G	1.0
D614G	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Gong et al. (2021)	147	A	G	1.0
D614G	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.69x decrease in binding (KD) relative to D614G.	B.1.621	Gong et al. (2021)	126	A	G	1.0
D614G	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.	B.1.621, BB.2, B.1.621.1	Gong et al. (2021)	133	A	G	1.0
D614G	ACE2 receptor binding affinity	In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone	B.1.621, BB.2, B.1.621.2, B.1.621.1	Li et al. (2020)	147	A	G	1.0
D614G	ACE2 receptor binding affinity	Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells for ACE2 affinity changes vs D614G alone, showing a extasciitilde70% drop in IC50 (i.e. increased affinity).	B.1.621	Tada et al. (2021)	126	A	G	1.0
D614G	antibody epitope effects	Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.	B.1.621	Hu et al. (2021)	126	A	G	1.0
D614G	convalescent plasma binding	1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Gong et al. (2021)	147	A	G	1.0
D614G	convalescent plasma binding	2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	B.1.621	Gong et al. (2021)	126	A	G	1.0

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
D614G	convalescent plasma binding	2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	B.1.621	Gong et al. (2021)	126	A	G	1.0
D614G	convalescent plasma binding	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Gong et al. (2021)	147	A	G	1.0
D614G	convalescent plasma binding	1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Gong et al. (2021)	147	A	G	1.0
D614G	convalescent plasma binding	1.56x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	B.1.621	Gong et al. (2021)	126	A	G	1.0
D614G	convalescent plasma binding	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	B.1.621, BB.2, B.1.621.1	Gong et al. (2021)	133	A	G	1.0
D614G	convalescent plasma escape	Average extasciitilde10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	B.1.621	Alenquer et al. (2021)	126	A	G	1.0
D614G	convalescent plasma escape	Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera collected extasciitilde8mo post Jan 2020 first wave in China).	B.1.621	Hu et al. (2021)	126	A	G	1.0
D614G	convalescent plasma escape	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	B.1.621, BB.2, B.1.621.2, B.1.621.1	Tada et al. (2021)	147	A	G	1.0
D614G	convalescent plasma escape	Lentiviral pseudotyped with the key mutations from COH.20G/677H ("Ohio") lineage was neutralized similarly to D614G in 10 convalescent sera from April 2020 infectees.	B.1.621	Tada et al. (2021)	126	A	G	1.0
D614G	convalescent plasma escape	Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]	B.1.621	Wilhelm et al. (2021)	126	A	G	1.0
D614G	immunosuppression variant emergence	Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Landis et al. (2021)	147	A	G	1.0
D614G	syncytium formation	Slight increase in Vero cell membrane fusion assay under infection with VSV pseudotyped virus.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kim et al. (2021)	147	A	G	1.0

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
D614G	syncytium formation	extasciitilde50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, significantly higher than D614G.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kim et al. (2021)	147	A	G	1.0
D614G	syncytium formation	Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kim et al. (2021)	147	A	G	1.0
D614G	tissue specific neutralization	The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal swab from different previously infected vaccinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against viral acquisition and infection of the oral-nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Planas et al. (2021)	147	A	G	1.0
D614G	trafficking	Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)	B.1.621, BB.2, B.1.621.2, B.1.621.1	Barrett et al. (2021)	147	A	G	1.0
D614G	trafficking	The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2. Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants, the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Daniloski et al. (2021)	147	A	G	1.0
D614G	trafficking	The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.	B.1.621	Hu et al. (2021)	126	A	G	1.0
D614G	trafficking	No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kim et al. (2021)	147	A	G	1.0
D614G	trafficking	extasciitilde4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kim et al. (2021)	147	A	G	1.0

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
D614G	trafficking	More efficient infectivity (24h) compared to wild type, in Caco-2 cells extasciitilde11x, Vero extasciitilde10x, and Calu-3 extasciitilde11x. Compare to wild type at extasciitilde5x across cell types.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kim et al. (2021)	147	A	G	1.0
D614G	trafficking	extasciitilde6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kim et al. (2021)	147	A	G	1.0
D614G	trafficking	More efficient infectivity (24h) compared to wild type, in Caco-2 cells extasciitilde9x, Vero extasciitilde8x, and Calu-3 extasciitilde8x. Compare to wild type at extasciitilde5x across cell types.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kim et al. (2021)	147	A	G	1.0
D614G	trafficking	extasciitilde4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kim et al. (2021)	147	A	G	1.0
D614G	trafficking	extasciitilde2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kuzmina et al. (2021)	147	A	G	1.0
D614G	trafficking	Approximately as infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction ( extasciitildeadditive effects of the individual variants).	B.1.621	Kuzmina et al. (2021)	126	A	G	1.0
D614G	trafficking	extasciitilde13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.	B.1.621	Kuzmina et al. (2021)	126	A	G	1.0
D614G	trafficking	extasciitilde12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction ( extasciitildeadditive effects of 501 and 484).	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kuzmina et al. (2021)	147	A	G	1.0
D614G	trafficking	extasciitilde2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	B.1.621	Kuzmina et al. (2021)	126	A	G	1.0
D614G	trafficking	extasciitilde9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).	B.1.621	Kuzmina et al. (2021)	126	A	G	1.0
D614G	trafficking	9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kuzmina et al. (2021)	151	A	G	1.0
D614G	trafficking	Among S variants tested, the D614G mutant shows the highest cell entry ( extasciitilde3.5x wild type), as supported by structural and binding analyses.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Ozono et al. (2020)	147	A	G	1.0
D614G	trafficking	Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection, showing no significant change in infection rate amongst the cells, suggesting that this mutation does not contributing to cell entry fitness.	B.1.621	Tada et al. (2021)	126	A	G	1.0



Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
D614G	trafficking	We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (extasciitilde9-fold). This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion. D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may increase infectivity by assembling more functional S protein into the virion.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Zhang et al. (2020)	147	A	G	1.0
D614G	transmissibility	Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure.	B.1.621	Pearson et al. (2021)	126	A	G	1.0
D614G	transmissibility	36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021 in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.	B.1.621	Roquebert et al. (2021)	126	A	G	1.0
D614G	transmissibility	Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type. [In combination with E484Q caused a lower 3-fold increase]	B.1.621	Tada et al. (2021)	126	A	G	1.0
D614G	vaccine neutralization efficacy	Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9 days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Garcia-Beltran et al. (2021)	147	A	G	1.0

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
D614G	vaccine neutralization efficacy	Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700) 21 to 63 days post-onset.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kuzmina et al. (2021)	147	A	G	1.0
D614G	vaccine neutralization efficacy	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kuzmina et al. (2021)	147	A	G	1.0
D614G	vaccine neutralization efficacy	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kuzmina et al. (2021)	147	A	G	1.0
D614G	vaccine neutralization efficacy	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	B.1.621	Kuzmina et al. (2021)	126	A	G	1.0
D614G	vaccine neutralization efficacy	This variant showed extasciitilde10x decrease in Pfizer sera (3 weeks post-first dose: n	B.1.621	Kuzmina et al. (2021)	126	A	G	1.0
D614G	vaccine neutralization efficacy	This variant of key B.1.351 lineage mutations showed extasciitilde10x decrease in Pfizer sera (3 weeks post-first dose: n	B.1.621	Kuzmina et al. (2021)	126	A	G	1.0
D614G	vaccine neutralization efficacy	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n	B.1.621	Kuzmina et al. (2021)	126	A	G	1.0
D614G	vaccine neutralization efficacy	This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kuzmina et al. (2021)	147	A	G	1.0

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
D614G	vaccine neutralization efficacy	In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from extasciitilde2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This RBD variant combination's neutralization by a placebo control group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	B.1.621	Madhi et al. (2021)	126	A	G	1.0
D614G	vaccine neutralization efficacy	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Tada et al. (2021)	147	A	G	1.0
D614G	vaccine neutralization efficacy	Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).	B.1.621	Wilhelm et al. (2021)	126	A	G	1.0
D614G	vaccine neutralization efficacy	No significant change in virus neutralization by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation]	B.1.621, BB.2, B.1.621.2, B.1.621.1	Zuckerman et al. (2021)	147	A	G	1.0

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
D614G	vaccinee binding plasma	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Gong et al. (2021)	147	A	G	1.0
D614G	vaccinee binding plasma	1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	B.1.621	Gong et al. (2021)	126	A	G	1.0
D614G	vaccinee binding plasma	1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	B.1.621	Gong et al. (2021)	126	A	G	1.0
D614G	vaccinee binding plasma	1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Gong et al. (2021)	147	A	G	1.0
D614G	vaccinee binding plasma	1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Gong et al. (2021)	147	A	G	1.0
D614G	vaccinee binding plasma	1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.22x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	B.1.621	Gong et al. (2021)	126	A	G	1.0

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
D614G	vaccinee plasma binding	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	B.1.621, BB.2, B.1.621.1	Gong et al. (2021)	133	A	G	1.0
D614G	viral load	Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs, supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Plante et al. (2020)	147	A	G	1.0
D614G	virion structure	Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type)	B.1.621, BB.2, B.1.621.2, B.1.621.1	Spratt et al. (2021)	147	A	G	1.0
D614G	virion structure	Negative stain EM shows increased proportion of "one-up" trimer conformation of Spike proteins on the surface of virions, where the up conformation is presumed to be more likely to bind ACE2.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Weissman et al. (2020)	147	A	G	1.0
D614G	virion structure	CryoEM shows increased proportion of "one-up" trimer conformation of Spike proteins on the surface of virions, where the up conformation is presumed to be more likely to bind ACE2.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Yurkovetskiy et al. (2020)	147	A	G	1.0
D614G	virion structure	Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Zhang et al. (2020)	147	A	G	1.0
E484K	ACE2 receptor binding affinity	The affinity of the B.1.351 RBD variants for ACE2 increased by 3.7 fold as measured by surface plasmon resonance relative to wild type RBD by increasing the k(on) and decreasing the k(off) rate constants.	B.1.621	Barton et al. (2021)	123	G	A	0.98
E484K	ACE2 receptor binding affinity	In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to extasciitilde15 fold higher than WT RBD (KD extasciitilde5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Barton et al. (2021)	144	G	A	0.98

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
E484K	ACE2 receptor binding affinity	This combination showed extasciitilde3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	B.1.621, BB.2, B.1.621.2, B.1.621.1	Collier et al. (2021)	144	G	A	0.98
E484K	ACE2 receptor binding affinity	This variant appears twice in the experiments, with slightly different affinities (both extasciitilde1.2x decrease in binding relative to D614G) using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Gong et al. (2021)	144	G	A	0.98
E484K	ACE2 receptor binding affinity	RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor, while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds 3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Laffeber et al. (2021)	144	G	A	0.98
E484K	ACE2 receptor binding affinity	Studying the key covariants in lineage of concern 501Y.V2, observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Liu et al. (2021)	144	G	A	0.98
E484K	ACE2 receptor binding affinity	Using Microscale Thermophoresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly five-fold greater affinity than the original SARS-CoV-2 RBD (Kd 87.6, vs 402.5 nM).	B.1.621, BB.2, B.1.621.2, B.1.621.1	Ramanathan et al. (2021)	144	G	A	0.98
E484K	ACE2 receptor binding affinity	Experimentally, ACE2 binding affinity increased 0.06 fold	B.1.621, BB.2, B.1.621.2, B.1.621.1	Starr et al. (2020)	144	G	A	0.98
E484K	ACE2 receptor binding affinity	Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd	B.1.621, BB.2, B.1.621.2, B.1.621.1	Tian et al. (2021)	144	G	A	0.98
E484K	ACE2 receptor binding affinity	Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd	B.1.621, BB.2, B.1.621.2, B.1.621.1	Tian et al. (2021)	144	G	A	0.98
E484K	ACE2 receptor binding affinity	The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Vogel et al. (2021)	144	G	A	0.98
E484K	ACE2 receptor binding affinity	Among the first selected variants in an in vitro evolution experiment for ACE2 binding.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Zahradnik et al. (2021)	144	G	A	0.98

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
E484K	T cell evasion	Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared to have no substantial or differential impact on T cell responses.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Reynolds et al. (2021)	144	G	A	0.98
E484K	antibody epitope effects	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Chen et al. (2021)	144	G	A	0.98
E484K	antibody epitope effects	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58.	B.1.621	Chen et al. (2021)	123	G	A	0.98
E484K	antibody epitope effects	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Chen et al. (2021)	144	G	A	0.98
E484K	antibody epitope effects	Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Collier et al. (2021)	144	G	A	0.98
E484K	antibody epitope effects	Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding, but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response) show pronounced increase in binding to the variant.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Gaebler et al. (2021)	144	G	A	0.98
E484K	antibody epitope effects	Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.	B.1.621	Hu et al. (2021)	123	G	A	0.98
E484K	antibody epitope effects	Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Li et al. (2021)	144	G	A	0.98
E484K	antibody epitope effects	Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistance to 4 antibodies, and broad low level resistance against much of the rest of the panel.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Liu et al. (2020)	144	G	A	0.98
E484K	antibody epitope effects	Massive reduction in binding efficiency vs wild type for mAb LY-CoV555.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Rappazzo et al. (2021)	144	G	A	0.98
E484K	antibody epitope effects	Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8	B.1.621, BB.2, B.1.621.2, B.1.621.1	Sun et al. (2021)	144	G	A	0.98
E484K	antibody epitope effects	Complete loss of binding in ELISA by the variant against monoclonal antibodies ab8 and IgG1 ab1. Complete loss for the same antibodies was also observed against S1 pseudotyped and full Spike protein trimers with both B.1.351 and P.1 lineage variants, with slight binding signal for P.1 against IgG1 at the highest concentration tested (1uM). Complete loss of neutralization by these two antibodies was also observed.	B.1.621	Sun et al. (2021)	123	G	A	0.98

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
E484K	antibody epitope effects	Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus)	B.1.621, BB.2, B.1.621.2, B.1.621.1	Wang et al. (2021)	144	G	A	0.98
E484K	antibody epitope effects	Resistant to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold or greater reduction in neutralization (plus notable reduction in two unclassified mAbs).	B.1.621, BB.2, B.1.621.2, B.1.621.1	Wang et al. (2021)	144	G	A	0.98
E484K	antibody epitope effects	Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 ("South African") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 ("South African") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 ("South African") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 ("South African") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 ("South African") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 ("South African") lineage background	B.1.621	Wibmer et al. (2021)	123	G	A	0.98
E484K	convalescent plasma binding	1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Gong et al. (2021)	144	G	A	0.98
E484K	convalescent plasma escape	Average extasciitilde5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Alenquer et al. (2021)	144	G	A	0.98
E484K	convalescent plasma escape	Average extasciitilde10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	B.1.621	Alenquer et al. (2021)	123	G	A	0.98
E484K	convalescent plasma escape	This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity	B.1.621, BB.2, B.1.621.2, B.1.621.1	Andreano et al. (2020)	144	G	A	0.98



Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
E484K	convalescent plasma escape	The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	B.1.621, BB.2, B.1.621.2, B.1.621.1	Cele et al. (2021)	144	G	A	0.98
E484K	convalescent plasma escape	In 19 convalescent human sera extasciitildelmo post infection had mild to moderate resistance against most samples	B.1.621	Chen et al. (2021)	123	G	A	0.98
E484K	convalescent plasma escape	In 19 convalescent human sera extasciitildelmo post infection had mild to moderate resistance against all samples.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Chen et al. (2021)	144	G	A	0.98
E484K	convalescent plasma escape	Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera collected extasciitilde8mo post Jan 2020 first wave in China).	B.1.621	Hu et al. (2021)	123	G	A	0.98
E484K	convalescent plasma escape	extasciitilde7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant.	B.1.621	Kuzmina et al. (2021)	123	G	A	0.98
E484K	convalescent plasma escape	Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested (triplicate experiments). Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Liu et al. (2021)	144	G	A	0.98
E484K	convalescent plasma escape	Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Schmidt et al. (2021)	144	G	A	0.98
E484K	convalescent plasma escape	The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction ( extasciitilde1.7x across 10 convalescent sera from April 2020 infectees)	B.1.621, BB.2, B.1.621.2, B.1.621.1	Tada et al. (2021)	144	G	A	0.98
E484K	convalescent plasma escape	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	B.1.621, BB.2, B.1.621.2, B.1.621.1	Tada et al. (2021)	144	G	A	0.98

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
E484K	convalescent plasma escape	As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for six batches of hyper-immune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Tang et al. (2021)	144	G	A	0.98
E484K	convalescent plasma escape	Demonstrate (via competitive assays in human and mouse) immune escape from polyclonal antibodies induced by vaccination or infection, comparable to what was previously shown with monoclonal antibodies for N501Y and more importantly for E484K. Even though viral mutations may more strongly affect monoclonal antibodies than sera activity, the latter may also be reduced as confirmed here.	B.1.621	Vogel et al. (2021)	123	G	A	0.98
E484K	convalescent plasma escape	The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model	B.1.621, BB.2, B.1.621.2, B.1.621.1	Wang et al. (2021)	144	G	A	0.98
E484K	convalescent plasma escape	27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutants of the 501Y.V2 "South African" lineage), while only 23% retained high titres	B.1.621, BB.2, B.1.621.2, B.1.621.1	Wibmer et al. (2021)	144	G	A	0.98
E484K	convalescent plasma escape	Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 ("South African") lineage pseudovirus construct. Only 3 of 44 convalescent sera (those with the highest titer, which correlated directly with initial infection severity) had high neutralization against this 501Y.V2 PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Wibmer et al. (2021)	144	G	A	0.98
E484K	convalescent plasma escape	Subtype of the B.1.526 "New York" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in IC50 serum dilution concentration for 6 convalescent sera.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Zhou et al. (2021)	144	G	A	0.98
E484K	monoclonal antibody serial passage escape	The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110).	B.1.621, BB.2, B.1.621.2, B.1.621.1	Barnes et al. (2020)	144	G	A	0.98
E484K	monoclonal antibody serial passage escape	Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage)	B.1.621, BB.2, B.1.621.2, B.1.621.1	Baum et al. (2020)	144	G	A	0.98

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
E484K	monoclonal antibody serial passage escape	Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody	B.1.621, BB.2, B.1.621.2, B.1.621.1	Greaney et al. (2020)	144	G	A	0.98
E484K	monoclonal antibody serial passage escape	In serial experiment of mAb 2B04 resistant mutation isolate E48K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Liu et al. (2021)	144	G	A	0.98
E484K	monoclonal antibody serial passage escape	Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	B.1.621, BB.2, B.1.621.2, B.1.621.1	Starr et al. (2021)	144	G	A	0.98
E484K	monoclonal antibody serial passage escape	Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Wang et al. (2021)	144	G	A	0.98
E484K	monoclonal antibody serial passage escape	Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages	B.1.621, BB.2, B.1.621.2, B.1.621.1	Weisblum et al. (2020)	144	G	A	0.98
E484K	pharmaceutical effectiveness	Bamlanivimab (LY-CoV555) lost extasci-tilde16x binding against this isolated mutation. Casirivimab lost extasci-tilde16x binding against this isolated mutation.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Engelhart et al. (2021)	144	G	A	0.98
E484K	pharmaceutical effectiveness	Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Engelhart et al. (2021)	144	G	A	0.98
E484K	pharmaceutical effectiveness	Bamlanivimab (LY-CoV555) lost extasci-tilde32x binding against this double mutation. COR-101 lost extasci-tilde160x binding against this double mutation. Casirivimab lost extasci-tilde16x binding against this double mutation. Estesevimab lost extasci-tilde32x binding against this double mutation. Regdanvimab lost extasci-tilde4x binding against this double mutation. Tixagevimab lost extasci-tilde12x binding against this double mutation.	B.1.621	Engelhart et al. (2021)	123	G	A	0.98

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
E484K	pharmaceutical effectiveness	Bamlanivimab (LY-CoV555) lost extasciitilde64x binding against this double mutation. COR-101 lost extasciitilde50x binding against this double mutation. Casirivimab lost extasciitilde250x binding against this double mutation. Estesevimab lost extasciitilde16x binding against this double mutation. Regdanvimab lost extasciitilde32x binding against this double mutation. Tixagevimab lost extasciitilde10x binding against this double mutation.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Engelhart et al. (2021)	144	G	A	0.98
E484K	pharmaceutical effectiveness	This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Liu et al. (2021)	144	G	A	0.98
E484K	syncytium formation	extasciitilde50% Vero cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, significantly higher than D614G.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kim et al. (2021)	144	G	A	0.98
E484K	trafficking	This variant alone shows a extasciitilde5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Ferriera et al (2021)	144	G	A	0.98
E484K	trafficking	This variant combination shows a extasciitilde4-5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G, same as L452R alone.	B.1.621	Ferriera et al (2021)	123	G	A	0.98
E484K	trafficking	The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.	B.1.621	Hu et al. (2021)	123	G	A	0.98
E484K	trafficking	More efficient infectivity (24h) compared to wild type, in Caco-2 cells extasciitilde11x, Vero extasciitilde10x, and Calu-3 extasciitilde11x. Compare to wild type at extasciitilde5x across cell types.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kim et al. (2021)	144	G	A	0.98
E484K	trafficking	extasciitilde6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kim et al. (2021)	144	G	A	0.98
E484K	trafficking	extasciitilde2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kuzmina et al. (2021)	144	G	A	0.98
E484K	trafficking	Approximately as infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction ( extasciitildeadditive effects of the individual variants).	B.1.621	Kuzmina et al. (2021)	123	G	A	0.98
E484K	trafficking	extasciitilde13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.	B.1.621	Kuzmina et al. (2021)	123	G	A	0.98

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
E484K	trafficking	extasciitilde12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (extasciitildeadditive effects of 501 and 484).	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kuzmina et al. (2021)	144	G	A	0.98
E484K	trafficking	Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection, showing no change in infection rate amongst the cells.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Tada et al. (2021)	144	G	A	0.98
E484K	transmissibility	Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure.	B.1.621	Pearson et al. (2021)	123	G	A	0.98
E484K	transmissibility	36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021 in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.	B.1.621	Roquebert et al. (2021)	123	G	A	0.98
E484K	vaccine neutralization efficacy	Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccine sera (collected 14 days after second dose) against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus.	B.1.621	Bates et al. (2021)	123	G	A	0.98
E484K	vaccine neutralization efficacy	The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P	B.1.621, BB.2, B.1.621.2, B.1.621.1	Chen et al. (2021)	144	G	A	0.98
E484K	vaccine neutralization efficacy	Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484K conferred a ten-fold reduction in neutralisation by vaccine sera.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Ferreira et al. (2021)	144	G	A	0.98

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
E484K	vaccine neutralization efficacy	E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine showed a mean 2.8x decrease in neutralization efficacy.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Ikegame et al. (2021)	144	G	A	0.98
E484K	vaccine neutralization efficacy	Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference USA-WA1/2020 strain. 8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference USA-WA1/2020 strain. One plasma failed to neutralize at all. 11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference USA-WA1/2020 strain. 11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference USA-WA1/2020 strain.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Jangra et al. (2021)	144	G	A	0.98
E484K	vaccine neutralization efficacy	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kuzmina et al. (2021)	144	G	A	0.98
E484K	vaccine neutralization efficacy	This variant showed extasciitilde10x decrease in Pfizer sera (3 weeks post-first dose: n	B.1.621	Kuzmina et al. (2021)	123	G	A	0.98
E484K	vaccine neutralization efficacy	This variant of key B.1.351 lineage mutations showed extasciitilde10x decrease in Pfizer sera (3 weeks post-first dose: n	B.1.621	Kuzmina et al. (2021)	123	G	A	0.98
E484K	vaccine neutralization efficacy	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n	B.1.621, BB.2, B.1.621.2, B.1.621.1	Kuzmina et al. (2021)	144	G	A	0.98
E484K	vaccine neutralization efficacy	In post-vaccination sera from individuals who received one (3 weeks post-first dose: n	B.1.621	Kuzmina et al. (2021)	123	G	A	0.98

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
E484K	vaccine neutralization efficacy	In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from extasciitilde2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This RBD variant combination's neutralization by a placebo control group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	B.1.621	Madhi et al. (2021)	123	G	A	0.98
E484K	vaccine neutralization efficacy	Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Janssen vaccine) against the variants containing the E484K substitution in the RBD were present but reduced (fold reduction between 3.35–7.78, 95% confidence interval all above twofold difference, one-sample t test).	B.1.621, BB.2, B.1.621.2, B.1.621.1	Solfrosi et al. (2021)	144	G	A	0.98
E484K	vaccine neutralization efficacy	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Tada et al. (2021)	144	G	A	0.98
E484K	vaccine neutralization efficacy	In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines, ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Wang et al. (2021)	144	G	A	0.98

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
E484K	vaccine neutralization efficacy	In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines, a significant (0.5 to 20-fold, but average extasciitilde2x) decrease in neutralization by vaccine plasma was observed.	B.1.621	Wang et al. (2021)	123	G	A	0.98
E484K	vaccine neutralization efficacy	In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases, titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of extasciitilde1/300.	B.1.621	Wu et al. (2021)	123	G	A	0.98
E484K	vaccine neutralization efficacy	In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Xie et al. (2021)	144	G	A	0.98
E484K	vaccinee plasma binding	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Gong et al. (2021)	144	G	A	0.98
E484K	viral load	B.1.351 and P.1 samples showed average Ct cycle threshold of 22.2 vs 23 for wildtype (i.e. extasciitilde60% higher viral load) comparing 3360 and 22535 samples respectively.	B.1.621	Roquebert et al. (2021)	123	G	A	0.98
E484K	viral load	The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a extasciitilde2-fold viral load increase ( extasciitilde1 Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26).	B.1.621	Teyssou et al. (2021)	123	G	A	0.98
E484K	virion structure	Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type)	B.1.621, BB.2, B.1.621.2, B.1.621.1	Spratt et al. (2021)	144	G	A	0.98
P681H	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Gong et al. (2021)	147	C	A	1.0
P681H	antibody epitope effects	Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Chen et al. (2021)	147	C	A	1.0



Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
P681H	antibody epitope effects	Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B.1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Haynes et al. (2021)	147	C	A	1.0
P681H	antibody epitope effects	This variant is adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Johnson et al. (2020)	147	C	A	1.0
P681H	convalescent plasma binding	1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Gong et al. (2021)	147	C	A	1.0
P681H	trafficking	While the introduction of P681H in the SARS-CoV-2 B.1.1.7 variant may increase spike cleavage by furin-like proteases, this does not significantly impact viral entry or cell-cell spread. We consider that other factors are at play to account for the increased in transmission and disease severity attributed to this variant of concern (VOC).	B.1.621, BB.2, B.1.621.2, B.1.621.1	Lubinski et al. (2021)	147	C	A	1.0
P681H	trafficking	This mutation in the first base of the furin cleavage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphatase recognition site at S680. In a homologous site in Infectious Bronchitis Virus (IBV, Gamma-coronaviruses), abolition of S680 phosphorylation improves furin cleavage (and presumably cell entry).	B.1.621, BB.2, B.1.621.2, B.1.621.1	Maaroufi (2021)	147	C	A	1.0
P681H	trafficking	Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection, showing NO statistically significant infection rate change amongst the cells, suggesting that furin cleavage typically used for cell entry is not affected by this change one amino acid upstream of the RXXR recognition pattern.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Tada et al. (2021)	147	C	A	1.0

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
P681H	vaccine neutralization efficacy	No significant change in virus neutralization by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation]	B.1.621, BB.2, B.1.621.2, B.1.621.1	Zuckerman et al. (2021)	147	C	A	1.0
P681H	vaccinee plasma binding	1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Gong et al. (2021)	147	C	A	1.0
P681H	virion structure	The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation, due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	B.1.621, BB.2, B.1.621.2, B.1.621.1	Tada et al. (2021)	147	C	A	1.0
T95I	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.	B.1.621, BB.2, B.1.621.1	Gong et al. (2021)	123	C	T	1.0
T95I	convalescent plasma binding	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	B.1.621, BB.2, B.1.621.1	Gong et al. (2021)	123	C	T	1.0
T95I	vaccinee plasma binding	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	B.1.621, BB.2, B.1.621.1	Gong et al. (2021)	123	C	T	1.0
R346K	gene expression increase	Experimentally, Spike gene expression increased 0.12 fold	B.1.621.2	Starr et al. (2020)	14	CAG	AAA	1.0
R346K	monoclonal antibody serial passage escape	In serial experiment of mAb 2B04 resistant mutation isolate E48K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination.	B.1.621.2	Liu et al. (2021)	14	CAG	AAA	1.0
R346K	monoclonal antibody serial passage escape	Strong positive selection (up to 53% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, overall 70% switch away from R346 to S, K or M	B.1.621.2	Weisblum et al. (2020)	14	CAG	AAA	1.0
R346K	gene expression increase	Experimentally, Spike gene expression increased 0.12 fold	B.1.621, BB.2, B.1.621.1	Starr et al. (2020)	133	G	A	1.0

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
R346K	monoclonal antibody serial passage escape	In serial experiment of mAb 2B04 resistant mutation isolate E48K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination.	B.1.621, BB.2, B.1.621.1	Liu et al. (2021)	133	G	A	1.0
R346K	monoclonal antibody serial passage escape	Strong positive selection (up to 53% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, overall 70% switch away from R346 to S, K or M	B.1.621, BB.2, B.1.621.1	Weisblum et al. (2020)	133	G	A	1.0
K417N	ACE2 receptor binding affinity	The K417N mutation decreased the affinity extasciitilde4 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.	B.1.621	Barton et al. (2021)	126	G	T	0.52
K417N	ACE2 receptor binding affinity	The affinity of the B.1.351 RBD variants for ACE2 increased by 3.7 fold as measured by surface plasmon resonance relative to wild type RBD by increasing the k(on) and decreasing the k(off) rate constants.	B.1.621	Barton et al. (2021)	126	G	T	0.52
K417N	ACE2 receptor binding affinity	This combination showed extasciitilde3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	B.1.621	Collier et al. (2021)	126	G	T	0.52
K417N	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.	B.1.621	Gong et al. (2021)	126	G	T	0.52
K417N	ACE2 receptor binding affinity	RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor, while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds 3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	B.1.621	Laffebber et al. (2021)	126	G	T	0.52
K417N	ACE2 receptor binding affinity	Studying the key covariants in lineage of concern 501Y.V2, observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	B.1.621	Liu et al. (2021)	126	G	T	0.52
K417N	ACE2 receptor binding affinity	Using Microscale Thermophoresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	B.1.621	Ramanathan et al. (2021)	126	G	T	0.52

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
K417N	ACE2 receptor binding affinity	Reported 3-fold decrease in affinity compared to wild-type RBD on the cell surface (Kd	B.1.621	Tian et al. (2021)	126	G	T	0.52
K417N	ACE2 receptor binding affinity	Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd	B.1.621	Tian et al. (2021)	126	G	T	0.52
K417N	ACE2 receptor binding affinity	The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	B.1.621	Vogel et al. (2021)	126	G	T	0.52
K417N	antibody epitope effects	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58.	B.1.621	Chen et al. (2021)	126	G	T	0.52
K417N	antibody epitope effects	Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.	B.1.621	Hu et al. (2021)	126	G	T	0.52
K417N	antibody epitope effects	>20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against IgG1 monoclonal antibody ab1.	B.1.621	Sun et al. (2021)	126	G	T	0.52
K417N	antibody epitope effects	Complete loss of binding in ELISA by the variant against monoclonal antibodies ab8 and IgG1 ab1. Complete loss for the same antibodies was also observed against S1 pseudotyped and full Spike protein trimers with both B.1.351 and P.1 lineage variants, with slight binding signal for P.1 against IgG1 at the highest concentration tested (1uM). Complete loss of neutralization by these two antibodies was also observed.	B.1.621	Sun et al. (2021)	126	G	T	0.52
K417N	antibody epitope effects	5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs)	B.1.621	Wang et al. (2021)	126	G	T	0.52
K417N	antibody epitope effects	Pseudotyped virus model ablates binding by RBD-directed mAbs CB6 and 910-30 (targeting the inner side of the RBD). Pseudotyped virus model impairs binding by RBD-directed mAbs 4-20 and REGN10933.	B.1.621	Wang et al. (2021)	126	G	T	0.52

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
K417N	antibody epitope effects	Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 ("South African") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 ("South African") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 ("South African") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 ("South African") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 ("South African") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 ("South African") lineage background	B.1.621	Wibmer et al. (2021)	126	G	T	0.52
K417N	convalescent plasma binding	2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	B.1.621	Gong et al. (2021)	126	G	T	0.52
K417N	convalescent plasma escape	Average extasciitilde10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	B.1.621	Alenquer et al. (2021)	126	G	T	0.52
K417N	convalescent plasma escape	The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	B.1.621	Cele et al. (2021)	126	G	T	0.52
K417N	convalescent plasma escape	In 19 convalescent human sera extasciitilde1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistance P	B.1.621	Chen et al. (2021)	126	G	T	0.52
K417N	convalescent plasma escape	In 19 convalescent human sera extasciitilde1mo post infection had mild to moderate resistance against most samples	B.1.621	Chen et al. (2021)	126	G	T	0.52
K417N	convalescent plasma escape	Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera collected extasciitilde8mo post Jan 2020 first wave in China).	B.1.621	Hu et al. (2021)	126	G	T	0.52

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
K417N	convalescent plasma escape	extasciitilde7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant.	B.1.621	Kuzmina et al. (2021)	126	G	T	0.52
K417N	convalescent plasma escape	Demonstrate (via competitive assays in human and mouse) immune escape from polyclonal antibodies induced by vaccination or infection, comparable to what was previously shown with monoclonal antibodies for N501Y and more importantly for E484K. Even though viral mutations may more strongly affect monoclonal antibodies than sera activity, the latter may also be reduced as confirmed here.	B.1.621	Vogel et al. (2021)	126	G	T	0.52
K417N	convalescent plasma escape	27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutants of the 501Y.V2 "South African" lineage), while only 23% retained high titres	B.1.621	Wibmer et al. (2021)	126	G	T	0.52
K417N	convalescent plasma escape	Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 ("South African") lineage pseudovirus construct. Only 3 of 44 convalescent sera (those with the highest titer, which correlated directly with initial infection severity) had high neutralization against this 501Y.V2 PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.	B.1.621	Wibmer et al. (2021)	126	G	T	0.52
K417N	gene expression increase	Experimentally, Spike gene expression increased 0.1 fold	B.1.621	Starr et al. (2020)	126	G	T	0.52
K417N	monoclonal antibody serial passage escape	Escape mutation against monoclonal antibody LY-CoV016	B.1.621	Starr et al. (2021)	126	G	T	0.52
K417N	monoclonal antibody serial passage escape	In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C682, and to a lesser extent C614 and C660	B.1.621	Wang et al. (2021)	126	G	T	0.52
K417N	pharmaceutical effectiveness	COR-101 lost extasciitilde6x binding against this isolated mutation. Estesevimab lost extasciitilde100x binding against this isolated mutation.	B.1.621	Engelhart et al. (2021)	126	G	T	0.52
K417N	pharmaceutical effectiveness	Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	B.1.621	Engelhart et al. (2021)	126	G	T	0.52

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
K417N	pharmaceutical effectiveness	Bamlanivimab (LY-CoV555) lost extasciitilde32x binding against this double mutation. COR-101 lost extasciitilde160x binding against this double mutation. Casirivimab lost extasciitilde16x binding against this double mutation. Estesevimab lost extasciitilde32x binding against this double mutation. Regdanvimab lost extasciitilde4x binding against this double mutation. Tixagevimab lost extasciitilde12x binding against this double mutation.	B.1.621	Engelhart et al. (2021)	126	G	T	0.52
K417N	pharmaceutical effectiveness	COR-101 lost extasciitilde20x binding against this double mutation. Estesevimab lost extasciitilde16x binding against this double mutation. Regdanvimab lost extasciitilde6x binding against this double mutation. M396 lost extasciitilde10x binding against this double mutation.	B.1.621	Engelhart et al. (2021)	126	G	T	0.52
K417N	pharmaceutical effectiveness	This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	B.1.621	Liu et al. (2021)	126	G	T	0.52
K417N	trafficking	The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.	B.1.621	Hu et al. (2021)	126	G	T	0.52
K417N	trafficking	extasciitilde2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	B.1.621	Kuzmina et al. (2021)	126	G	T	0.52
K417N	trafficking	Approximately as infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction (extasciitildeadditive effects of the individual variants).	B.1.621	Kuzmina et al. (2021)	126	G	T	0.52
K417N	trafficking	extasciitilde13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.	B.1.621	Kuzmina et al. (2021)	126	G	T	0.52
K417N	trafficking	extasciitilde9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).	B.1.621	Kuzmina et al. (2021)	126	G	T	0.52
K417N	trafficking	Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection, showing mild decrease in infection rate amongst the cells, suggesting that this mutation does not contributing to cell entry fitness.	B.1.621	Tada et al. (2021)	126	G	T	0.52

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
K417N	transmissibility	Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure.	B.1.621	Pearson et al. (2021)	126	G	T	0.52
K417N	transmissibility	36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021 in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.	B.1.621	Roquebert et al. (2021)	126	G	T	0.52
K417N	vaccine neutralization efficacy	Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccine sera (collected 14 days after second dose) against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus.	B.1.621	Bates et al. (2021)	126	G	T	0.52
K417N	vaccine neutralization efficacy	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	B.1.621	Kuzmina et al. (2021)	126	G	T	0.52
K417N	vaccine neutralization efficacy	This variant showed extasciitilde10x decrease in Pfizer sera (3 weeks post-first dose: n	B.1.621	Kuzmina et al. (2021)	126	G	T	0.52
K417N	vaccine neutralization efficacy	This variant of key B.1.351 lineage mutations showed extasciitilde10x decrease in Pfizer sera (3 weeks post-first dose: n	B.1.621	Kuzmina et al. (2021)	126	G	T	0.52
K417N	vaccine neutralization efficacy	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n	B.1.621	Kuzmina et al. (2021)	126	G	T	0.52
K417N	vaccine neutralization efficacy	In post-vaccination sera from individuals who received one (3 weeks post-first dose: n	B.1.621	Kuzmina et al. (2021)	126	G	T	0.52



Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
K417N	vaccine neutralization efficacy	In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from extasciitilde2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This RBD variant combination's neutralization by a placebo control group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	B.1.621	Madhi et al. (2021)	126	G	T	0.52
K417N	vaccine neutralization efficacy	In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines, a significant (0.5 to 20-fold, but average extasciitilde2x) decrease in neutralization by vaccine plasma was observed.	B.1.621	Wang et al. (2021)	126	G	T	0.52
K417N	vaccine neutralization efficacy	In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases, titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of extasciitilde1/300.	B.1.621	Wu et al. (2021)	126	G	T	0.52
K417N	vaccinee plasma binding	1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	B.1.621	Gong et al. (2021)	126	G	T	0.52
K417N	viral load	B.1.351 and P.1 samples showed average Ct cycle threshold of 22.2 vs 23 for wildtype (i.e. extasciitilde60% higher viral load) comparing 3360 and 22535 samples respectively.	B.1.621	Roquebert et al. (2021)	126	G	T	0.52

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
K417N	viral load	The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a 2-fold viral load increase ( Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26).	B.1.621	Teyssou et al. (2021)	126	G	T	0.52
K417N	virion structure	Estimated free energy change (ddG) for this variant is -0.86 kcal/mol (i.e. destabilizing relative to wild type)	B.1.621	Spratt et al. (2021)	126	G	T	0.52

The results here are in whole or part based upon data hosted at the Canadian VirusSeq Data Portal: <https://virusseq-dataportal.ca/>. We wish to acknowledge the following organisations/laboratories for contributing data to the Portal: Canadian Public Health Laboratory Network (CPHLN), CanCOGGeN VirusSeq and the list of labs available at <https://virusseq-dataportal.ca/acknowledgements>)